Related Experiment Video
Updated: Sep 15, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Reversal of MPPa-PDT Resistance in Osteosarcoma by Targeting ROCK2-Mediated Autophagy.
Xuan Yi1,2,3,4, Xueqiang Deng1,5, Jianyong Deng6
1Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Targeting Rho-associated coiled-coil containing protein kinase 2 (ROCK2) reverses resistance to pyropheophorbide-a methyl ester-Photodynamic therapy (MPPa-PDT) in osteosarcoma. Inhibiting ROCK2 decreases autophagy and restores MPPa-PDT sensitivity, offering new therapeutic strategies for osteosarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma (OS) is a malignant bone tumor with poor prognosis, often developing resistance to treatments like pyropheophorbide-a methyl ester-Photodynamic therapy (MPPa-PDT).
- Understanding the mechanisms of MPPa-PDT resistance is crucial for improving therapeutic outcomes in osteosarcoma patients.
Purpose of the Study:
- To investigate the role of Rho-associated coiled-coil containing protein kinase 2 (ROCK2) in MPPa-PDT resistance in osteosarcoma.
- To elucidate the molecular mechanisms by which ROCK2 influences MPPa-PDT sensitivity, focusing on autophagy and the Hippo signaling pathway.
Main Methods:
- Assessed ROCK2 expression in osteosarcoma cells post-MPPa-PDT treatment.
- Investigated the effect of ROCK2 inhibition on osteosarcoma cell sensitivity to MPPa-PDT and cellular autophagy levels.
- Conducted rescue experiments to confirm ROCK2's role in mediating resistance via autophagy regulation.
- Analyzed the interaction between ROCK2, SAV1, and MST1 within the Hippo signaling pathway.
- Correlated ROCK2 expression and Hippo pathway activity with clinical osteosarcoma patient prognosis.
Main Results:
- ROCK2 expression was upregulated in osteosarcoma cells following MPPa-PDT treatment.
- Inhibition of ROCK2 sensitized osteosarcoma cells to MPPa-PDT and reduced autophagy.
- ROCK2 was found to mediate MPPa-PDT resistance by regulating autophagy through the Hippo signaling pathway.
- ROCK2 competes with MST1 for SAV1 binding, inhibiting Hippo pathway activation and promoting MPPa-PDT resistance.
- Clinical data confirmed ROCK2 as an independent prognostic factor associated with worse outcomes in osteosarcoma patients.
Conclusions:
- ROCK2 plays a critical role in mediating MPPa-PDT resistance in osteosarcoma by regulating autophagy via the Hippo signaling pathway.
- Targeted inhibition of ROCK2, for example, using J059-0149, represents a promising strategy to overcome MPPa-PDT resistance.
- This study provides novel therapeutic targets and insights for enhancing the clinical efficacy of MPPa-PDT in osteosarcoma treatment.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation

